3 Jaw-dropping Stats From the Pot Stock Plunge

Canopy Growth stock, Aurora Cannabis stock, and Aphria stock took a nosedive this year, and none of the companies have pulled back up yet.

| More on:
edit Business accounting concept, Business man using calculator with computer laptop, budget and loan paper in office.

Image source: Getty Images

The green industry of cannabis is reporting a lot of red this year. Even the second phase of legalization didn’t provide a boost to the cannabis industry.

If you bought Cannabis stocks and are watching in horror as they plunge, you might find the numbers from three big players even more nightmarish.

Statistics from Canopy Growth (TSX:WEED)(NYSE:WEED), Aurora Cannabis (TSX:ACB)(NYSE:ACB), and Aphria (TSX:APHA)(NYSE:APHA) have seen some truly abysmal numbers this year.

A lot of these numbers can be associated with the industry’s downfall in general. But whether it’s the company’s weaknesses or the industry’s bad image, the result is bad news for investors.

Largest cannabis company

With the current market cap of $6.54 billion, Canopy Growth is still the largest marijuana company in the country. Until April 2019, it was the largest in the world, but the company’s market cap came crashing down and has been falling ever since.

Canopy reached its peak market cap in the latter half of April 2019, hitting almost $22.9 billion. That’s depreciation of more than 70% in just seven months.

The market cap has been cut down to half in only two months — a grim but astounding statistic, especially coming from the market leader in the sector that doubled investors’ money in a single year.

The most beaten-down stock

Aurora, another market leader in the green pot industry, is continually showing up in red for investors. This $3.15 billion cannabis giant adopted a strategy of aggressive acquisitions.

But the method Aurora chose to fund its assets has been questioned by experts, and with good reason. The company diluted so much that the current number of outstanding Aurora shares is more than a billion.

This dilution is one of the reasons why the company has traded in the single digits for most of its lifetime. The current market value of the company is $3 per share at writing.

This share price translates to a disastrous decrease of almost 62.5% from the same time this year and a 77% decrease from the yearly high.

An underdog

Aphria has been considered one of the underdogs of the industry, yet it has shown remarkable potential. The Q1 results last month represented a second consecutive quarter of positive numbers. It’s remarkable given the overall condition of the industry.

However, even the better-than-expected quarterly earnings didn’t stop Aphria from sinking with the ship. The market value is down almost 20% since the quarterly report and nearly 65% from the yearly high.

While Aphria might seem a better choice compared to the rest of the bunch, the fact remains that its stats are just as jaw-dropping as that of the industry leaders.

Foolish takeaway

If we judge by the numbers, it wouldn’t be incorrect to say that the country’s cannabis industry is falling apart. But more factors are driving the industry down than the companies’ failure to deliver.

The restrictions and delays by the licensing bodies, an unregulated black market, and the overall negative momentum are all responsible too.

There may still be a silver lining, however. The true potential of the second wave of legalization is yet to be seen. If the companies can create a decent presence in the cannabis products industry, they could flourish, and investors may capitalize on buying into the companies when the market values are an all-time low.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »